Early, Late-Stage, and Metastatic Liver (Hepatic) Cancer Treatment
Options
Helping Patients Overcome Liver (Hepatic) Cancer with
Personalized Precision Treatment Options
If you have an early or late-stage liver cancer diagnosis, you should know that you have found the right place
because
our unique and powerful personalized precision treatment approaches have helped thousands of patients, even those with
inoperable liver tumors.
For the last 25 years at Envita Medical Centers, a world-class integrative center for Precision Oncology, our
proprietary new treatments have been revolutionizing the cancer world with personalized targeted therapies and
advanced
immunotherapies.
Irrespective of the stage or type of cancer, we combine our genetically driven treatment approach with targeted
immunotherapies to not only uproot the disease, but also to improve the overall health of the patient. Our oncologists
take liver cancer treatment to the next level by integrating the latest in conventional medicine with research-based
natural therapies, which have proved effective in both late as well as early-stages of liver cancer.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
This article covers basic facts about liver cancer, including:
Difference Between Liver Cancer and Liver Metastases
Liver Cancer / Primary Liver Cancer
Cancer originating in the liver
May spread to surrounding blood vessels, lymph nodes, and
other
near
or distant parts of the body, causing metastatic
liver cancer
Less common than secondary liver cancer
Liver Metastases / Secondary Liver Cancer
Cancer originating in any part of the body, other than the
liver
but
has spread to the liver
Generally, cancer originating in the pancreas, colorectal
region,
or
stomach, may spread to the liver
More common than primary liver cancer
How Does Envita Go Beyond Standard Liver Cancer Treatments?
Our advanced integrative treatment approach gives us the liberty to break away from the standard NCCN (National
Comprehensive Cancer Network) guidelines, which dictate treatment at all major cancer hospitals.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
At Envita, we bring the latest developments in cancer research from around the world to help our patients recover
holistically. Our personalized treatments go beyond these one-size-fits-all protocols determined by the type and
disease
staging system, to impact the cancer drivers of each individual patient. This customized approach may reduce chances
of
recurrence or metastasis, leading to long-term remissions.
Standard treatment of liver cancer generally includes partial hepatectomy, also called liver resection to surgically
remove cancerous tumors, liver transplant, ablations, chemoembolization, radioembolization, chemotherapies, or
radiation
therapies. However, these standard treatments may not be effective enough, underlining the reason behind liver cancer
being the sixth
leading cause of cancer deaths in the United States. Despite advances in prevention techniques, screening, and
new technologies
in both diagnosis and treatment, incidence and mortality continue
to rise.
According to the American Cancer Society’s report
based on patient outcomes across standard cancer centers, which typically follow
the NCCN guidelines, the 5-year relative survival
rate of liver cancer is 20% which drops to a dismal 3% when the disease spreads to distant parts of the
body.
To counter these statistics, we personalize the treatment plan for each individual patient helping them progress
towards
a disease-free survival. Our personalized treatments help to reduce chances of disease recurrence or spread to other
parts of the liver in the early stages, while in late stages our treatments may arrest further spread to distant parts
of the body and help patients respond better to care.
Personalized Treatment Options May Work Better Than Clinical
Trials
Envita Medical Centers’ personalized precision oncology treatments may be a better option than clinical trials,
because we custom-build treatment plans based on each patient’s unique liver cancer biomarkers.
Biomarkers may be proteins, enzymes, any other substances, or processes, which are indicative of the presence of
cancer
in the body. At Envita, we aim to affect the unique set of biomarkers causing each patient’s individual liver cancer,
which helps in treating the disease at its core while improving the patient’s liver function and their general health.
Cancer is a disease of genetic mutations, and genetics differ from person to person, which highlights the
need for
personalization in cancer care.
Common Types of Liver Cancer
As described by the National Cancer
Institute, based on the cellular origin of the disease, liver cancer is commonly
categorized into:
Hepatocellular carcinoma (HCC)- accounts for more
than 80% of primary liver cancers
Fibrolamellar variant of HCC
Cholangiocarcinoma (intrahepatic bile duct carcinoma)
Mixed hepatocellular cholangiocarcinoma
Undifferentiated
Hepatoblastoma
Envita Medical Centers Medical Team
Physicians with MD, MD(h), and NMD medical
licenses, including certified oncologists, and certified interventional radiologists,
striving to provide the latest cancer innovations
22
Pharmacists specializing in integrative agents
7
Nurses trained in precision treatment delivery
40+
Envita’s Unique New Treatments Overcome Challenges for Optimal Results
Our multi-disciplinary team of healthcare professionals work collaboratively to develop a personalized treatment plan
which overcomes standard treatment challenges such as chemotherapeutic
drug resistance.
According to medical studies, with
extended administration of the first-line therapy for advanced stages of HCC, cancer cells can become resistant
to the drug, making it ineffective.
To tackle these challenges, our unique new treatments utilize a personalized combination therapy, which includes a
targeted blend of natural compounds, chemotherapeutics, immunotherapies, and precision methods of drug deployment.
With
over two decades of clinical experience, Envita Medical Centers has been able to overcome many of the challenges
associated with hepatic cancer treatment planning. Our advanced integrative treatment options and procedures go beyond
the standard protocols, enabling our patients to find personalized precision treatment options where other renowned
cancer treatment centers in the country are lacking.
Envita’s Precision Oncology Provides Important Quality of Life Metrics
88%*of patients reported symptom score improvement under Envita Medical
Centers’ Care
95%*fewer side-effects are experienced by patients receiving precision
oncology at Envita Medical Centers
With increased symptom score improvement and fewer side effects, Envita’s four-pillared treatment approach is aimed
at
providing lasting results. We build a detailed medical blueprint for each individual patient based on these four core
steps. Our personalized precision oncology treatment approach is designed to improve patients’ quality of life,
increase
longevity, and reduce toxicity.
Step 1
Genomic Identification Strikes at the Root Cause
Addressing all the causative factors of each patient’s liver cancer is crucial to provide the best possible chance of
a
holistic recovery. In our clinical opinion, if the cause of the cancer is not properly addressed, patients end up
receiving only palliative treatment meant to optimize quality of life and mitigate suffering.
To get to the root cause of each patient’s liver cancer, we perform an extensive genomic analysis, which is not
accessible to all liver cancer patients following standard treatment protocols.
At Envita, we perform in-depth genetic tests for all liver cancer patients, irrespective of their cancer stage or
type!
The handful of patients who do get access to genomic analysis as part of standard precision oncology, receive a
watered-down version of Envita’s detailed liver cancer program. Our proprietary genomic analysis investigates many more parameters than standard
oncology genomic testing, allowing us to build a comprehensive plan for
attacking liver cancer, while enhancing the patient’s immune system.
Envita Precision Algorithm vs. Standard Oncology Precision Testing
Envita Medical Centers
Standard Oncology Precision Testing
RNA Transcriptome Genes
Envita Medical Centers:20,000+
Standard Oncology:Unchecked
SNV/CNV Genes
Envita Medical Centers:452
Standard Oncology:309
Rearrangements/Fusion Genes
Envita Medical Centers:51
Standard Oncology:27
Microsatellite Instability (MSI)
Envita Medical Centers:Checked
Standard Oncology:Checked
Tumor Mutation Burden (TMB)
Envita Medical Centers:Checked
Standard Oncology:Checked
BRCA 1/2
Envita Medical Centers:Checked
Standard Oncology:Checked
Immunohistochemistry
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Chemosensitivity
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Concurrent Liquid Biopsy
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Exosomal miRNA Analysis
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Circulating Tumor Cells Enumeration
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Pharmacogenomics
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Individualized Therapy Recommendation
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Carcinogenic Exposure - Root Causes
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Inflammation Markers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Metabolic Target Drivers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
If the cause of the cancer is not properly addressed, then the likelihood of recurrence is much higher. Hepatitis,
for
instance, is a major risk factor for developing HCC. Medical studies show approximately 80% of cases of
HCC are associated with cirrhosis related to chronic hepatitis B virus (HBV) or
hepatitis C virus (HCV) infection.
Cirrhosis refers to severe scarring of liver tissues caused by long-term exposure to toxins, like alcohol, or certain
infections. At Envita, we are extremely experienced in identifying and treating cancer and its infectious causes, which
is why we have published extensively on this topic.
Envita’s personalized treatments address the pathways of cancer progression by incorporating aspects such as
inflammatory markers, oncogene downregulation, tumor suppressor gene upregulation, and advanced immunotherapy, to
treat
the disease core. In our clinical opinion, it is not enough to treat liver cancer alone because treating chronic
infections and associated liver diseases is pivotal for providing a comprehensive cancer treatment.
Step 2
Immuno Targeting Checks Further Metastases
The immune system is the first line of defense against cancer and is one of the greatest weapons for cancer
treatment,
which is why we provide advanced immunotherapy for all our patients,
irrespective of cancer stage or type.
Our personalized immunotherapies go beyond basic checkpoint inhibitors or smart drugs to treat patients with
late-stage
and complex cancers. Our pioneering research and experience in immunotherapy have led us to publish a study on
“Immunotherapy in Cancer Treatment”,
which
explains its potential to treat cancer with significantly less toxicity than chemotherapy and radiation
treatments.
Envita’s Ultra Analytes Liquid Biopsy helps in establishing immunotherapy targets, which facilitates proactive
treatment
of the disease, reducing chances of metastases. Our proprietary liquid biopsy utilizes blood tests to analyze
Circulating Tumor Cells (CTCs), which break away from a growing tumor and enter a patient’s bloodstream, spreading the
disease to various parts of the body.
Detailed analysis of CTCs establishes the chemo and immunotherapy targets of each individual liver cancer patient,
guiding us to the appropriate anti-cancer medications with the highest chance of tumor response.
A recent medical study on Current Perspectives in Immunotherapy
for Liver Cancer show how treatments in development involving cancer vaccines and natural killer cell-mediated
therapy may be beneficial
for patients. However, we at Envita are already offering these advanced treatments to help our patients outperform
this
disease.
Step 3
Personalized Drug Design May Debulk Liver Tumors
In our clinical opinion, a personalized combination of FDA (Food and Drug Administration) approved drugs,
repurposed
drugs, and custom-compounded adjuvants are critical for effectively striking at each patient’s unique liver
cancer. This
personalized drug design may help in debulking liver
tumors, thus helping in tackling certain unresectable cancers.
FDA Approved Drugs
Optimized for your cancer mutations.
Repurposed Drugs
Off-label use of approved medications
Custom Compounded Adjuvants
Genetically typed for each patient.
At Envita, treatment is not limited to the existing drugs available on the market, as we custom-design adjuvants at
our
in-house pharmacy to impact the unique set of
biomarkers, causing the disease and its progression in each individual patient. These
adjuvants are based on advanced phytotherapeutics, including plant extracts and herbs, which have proven impactful
against specific cancer biomarkers, without causing severe side effects.
Step 4
Precision Deployment for Better Results
Our proprietary new treatments utilize precision deployment mechanisms to deliver targeted therapies to the affected
area, without damaging the healthy cells in the adjoining regions. We deploy these powerful combinations of
personalized
medications either intravenously or through minimally invasive interventional radiology procedures.
At Envita, you gain access to our proprietary treatments as well as the latest offerings in standard liver cancer
treatment, but we enhance their efficacy by including advanced immunotherapy in the care plan of each individual
patient. For example, we do all types of ablations, such as radiofrequency ablations, cryoablations, and microwave
ablations, but we follow-up with targeted immunotherapies for each individual liver cancer patient to enhance the
efficacy of these procedures.
The following are some of our proprietary treatments:
CIPI™ (Chemo Immuno Precision Injections)
CIPI™, or Chemo Immuno Precision Injections, is a proprietary form of tumor embolization that Envita utilizes to
treat
inoperable or fibrous tumors. It is extremely useful for treating liver cancer and liver metastases because it can
circumvent factors that traditionally make this cancer challenging to treat.
Not only is liver cancer often inoperable, but it may even resist penetration by normal chemotherapy methods due to the thick stroma around the
tumor. However, our proprietary procedure is specially designed to overcome
all these hurdles.
Unlike other tumor embolization methods, like hepatic artery embolization or Trans arterial Chemoembolization (TACE),
CIPI™ takes a step further to deploy personalized chemotherapy and immunotherapy agents directly at the site of the
tumor. Targeted chemotherapy and adjunctive immune modulating agents are injected into the tumor through a thin
catheter
for precision absorption of medications directly into the tumor. These personalized medications make CIPI™ go beyond other forms of tumor embolization,
as it creates a systemic immune response that works to attack metastasized
cancer cells elsewhere in the body.
Envita's CIPI™ vs. Standard Surgery
Envita Medical Centers
Standard Surgery
Minimally invasive so it can be performed within 40-50 minutes, without the need for large surgical
incisions.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Can be performed multiple times, even at close intervals, because there is minimal risk of post-op
complications.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
No need for general anesthesia, reducing the health risks that can result from being put into a
medically induced coma to perform an invasive surgery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Faster recovery time as compared to traditional surgery, due to the minimally invasive administration.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Provides direct tumor targeting, which delivers patient-specific genomic agents into the tumor.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Causes a systemic immune response where the immune system is reactivated to find and attack other
metastatic cancer sites in the body.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Performed by highly trained medical professionals in an outpatient setting, so there is no need of
hospital stays for recovery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Envita Medical Centers’ proprietary precision targeted low-dose chemotherapy has the potential to help patients
respond
better than standard untargeted chemotherapy, as GTFC™ includes micro-dosed medications with the highest potential of
impacting each patient’s unique cancer biomarkers.
Our peer-reviewed and published study discusses
the importance of the use of biomarkers to enhance decision making with regard to the molecular profile of a
person’s cancer.
The targeted medications enable GTFC™ to perform at a precision level over standard maximum dose chemotherapy, which
is
generally used in advanced stages of liver cancer when patients do not respond to other treatments. However, GTFC™’s low dose targeted medications have a higher potential of
impacting
the cancer while causing fewer side-effects, as
compared to standard untargeted chemotherapy.
Envita's GTFC™ vs. Standard Chemotherapy
Envita Medical Centers
Standard Chemotherapy
Helps to improve chemotherapy delivery to the tumor using a "Trojan Horse" delivery mechanism.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses genetic molecular profiling to understand all the facets of each patient's specific cancer.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses targeted treatment to enhance the mechanism of cancer kill.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses microdosed (fractionated) chemotherapies, reducing the chances of impacting healthy cells.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Minimizes toxicity to normal cells, lowering the chance of side-effects related to administration.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses patient-specific supportive immunotherapy to strengthen the immune system.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Aims to reduce multidrug resistance by administering 10 - 20% of the medication delivered in maximum dose
chemo.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Allows custom-compounded medications to be readministered in tandem to suit each patient's individual cancer
mutations.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Watch Out for These Liver Cancer Symptoms
Jaundice, marked by yellowing of the skin and eyes
Weight loss
Loss of appetite
Fatigue
Pain in the abdomen
Nausea or vomiting
Cirrhosis, a late-stage liver disease, determined via blood-tests, imaging tests, like CT scan and MRI, or liver
biopsy
Call Us Now
While some patients may find success with conventional treatment methods, the vast majority of patients we treat at
Envita have already exhausted the traditional methods and are seeking more advanced care. Our clinical experience with
liver cancer and other inoperable tumors has led to the development of specialized treatment options which may be
beneficial for patients. Our multi-disciplinary team goes through 1,500 hours of training to adapt to this integrative
personalized precision oncology approach.
If you or a loved one has any questions regarding liver cancer, do not hesitate to call us at 866-830-4576. We are
looking forward to hearing from you. May God bless you on your journey to healing!
* The 3rd party actuarial response data is based on an analysis of records for 87 out
of 129 patients that participated in Envita’s Treatment Program in 2020. 42 patients were removed from the cohort due
to the patients’ inability to start or complete Envita’s prescribed treatment for a variety of reasons, including but
not limited to, advanced disease state, disease progression, or inability to travel.
Our team is ready to help you get your life back! Please enter your contact information and a Patient Care
Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576.
